1 This
multicenter 3-arm, parallel-group, patient-randomized co
2 d-state associations were also stabilized by
multicenter (
4:4) halogen bonding between I(4) Q(-.) and
3 Here we report the results from a
multicenter,
8-week, double-blind, placebo-controlled, r
4 1123 men (589 HIV+ and 534 HIV-) from MACS (
Multicenter AIDS Cohort Study), using the ZioXT ambulato
5 This is a retrospective
multicenter analysis of commercial insurance claims from
6 In a large
multicenter and highly phenotyped prospective cohort of
7 We report a large-scale
multicenter assessment of virological suppression over t
8 nalysis were included from the international
multicenter BAV TAVR registry.
9 The analysis of the
multicenter C3PO-QI registry was limited to patients who
10 Adult patients in a
multicenter,
Chicago-wide database of medical records wi
11 moderate to severe CKD participating in the
multicenter Chronic Renal Insufficiency Cohort (CRIC) St
12 D PARTICIPANTS: A parallel-group, randomized
multicenter clinical trial in 26 centers across Germany
13 TING, AND PARTICIPANTS: Randomized, blinded,
multicenter clinical trial of ascorbic acid, corticoster
14 erformed a randomized, adaptive, open-label,
multicenter clinical trial.
15 We conducted a
multicenter,
cluster-randomized, crossover trial compari
16 can cohort and validated in an international
multicenter cohort (n = 278).
17 A retrospective
multicenter cohort analysis of patients who underwent pa
18 Cross-modal analysis of a
multicenter cohort of 59 COQ8A patients, including genot
19 ere studied in the GULF-COAST, a prospective
multicenter cohort of acute coronary syndrome (ACS), in
20 ng drugs (OGLDs), with validation in another
multicenter cohort of Hong Kong Diabetes Biobank.
21 We enrolled a prospective,
multicenter cohort of ICU survivors with shock or respir
22 factor Xa inhibitor-related ICH in a large,
multicenter cohort of patients.
23 We conducted an international,
multicenter cohort study including 7 hospitals in New Yo
24 Multicenter cohort study including a total of 270 patien
25 This is a retrospective
multicenter cohort study including patients with chronic
26 We conducted a
multicenter cohort study of 3099 critically ill adults w
27 This is an international,
multicenter cohort study of adult deceased donor LT requ
28 We analyzed data from a
multicenter cohort study of adults with laboratory-confi
29 GN, SETTING, AND PARTICIPANTS: Retrospective
multicenter cohort study of patients from a random sampl
30 We performed a retrospective
multicenter cohort study of patients with cirrhosis diag
31 nts' Health Status) registry, a longitudinal
multicenter cohort study of people with acute myocardial
32 A retrospective,
multicenter cohort study was conducted across all single
33 er 2015 were included in this retrospective,
multicenter cohort study which included a propensity sco
34 This is a
multicenter cohort study, including patients with HCV an
35 In this international,
multicenter cohort study, left ventricular unloading was
36 In this
multicenter cohort study, we integrated allograft microa
37 This was a prospective
multicenter cohort study.
38 rs and the risk for diabetic ketoacidosis: a
multicenter cohort study.
39 ell carcinoma lesions from 2008 to 2019 in a
multicenter cohort were retrospectively identified.
40 LWH aged >=70 years from the Dat'AIDS French
multicenter cohort.
41 th those of the four grading systems using a
multicenter cohort.
42 Five models were derived from large
multicenter cohorts: the European Registry for Patients
43 SQ2-CPVT was sought through an international
multicenter collaboration.
44 A phase II single-arm
multicenter cooperative-group trial was conducted in pos
45 DESIGN, SETTING, AND PARTICIPANTS: A
multicenter cross-sectional study was performed in pedia
46 In this
multicenter cross-sectional study, we performed an egoce
47 There are limited
multicenter data comparing an active drug versus placebo
48 is a technique, enabling training models on
multicenter data without data leaving the hospitals ("pr
49 heia Study was a prospective, international,
multicenter,
diagnostic management study involving patie
50 In independent
multicenter discovery (CTOT14) and single-center validat
51 We conducted a
multicenter,
double-blind trial in which patients with t
52 We performed a
multicenter,
double-blind trial in which patients with t
53 diate cardiovascular markers, we conducted a
multicenter,
double-blind trial, randomizing 278 partici
54 We conducted a phase 3
multicenter,
double-blind, event-driven, randomized-with
55 DESIGN, SETTING, AND PARTICIPANTS:
Multicenter,
double-blind, parallel-group, randomized cl
56 In this
multicenter,
double-blind, phase III study, 418 patients
57 This was a
multicenter,
double-blind, placebo-controlled study rand
58 We performed a
multicenter,
double-blind, placebo-controlled trial, fro
59 with Icosapent Ethyl-Intervention Trial), a
multicenter,
double-blind, placebo-controlled trial, ran
60 The MAVERICK-HCM trial was a
multicenter,
double-blind, placebo-controlled, dose-rang
61 This randomized,
multicenter,
double-blind, placebo-controlled, phase III
62 The PIONEER-HF trial was a prospective,
multicenter,
double-blind, randomized clinical trial enr
63 DESIGN, SETTING, AND PARTICIPANTS:
Multicenter,
double-blinded, randomized clinical trial a
64 he patients participated in the prospective,
multicenter EuroNet-PHL-C1 study.
65 We used a
multicenter European cohort of 1076 female and male indi
66 Participants with rhinitis from 2
multicenter European cohorts (Epidemiological Study on t
67 rospectively included from the multinational
multicenter European Society of Cardiovascular Radiology
68 The Pronuts study is a
multicenter European study (London, Geneva, and Valencia
69 We performed a
multicenter evaluation of the investigational use of the
70 a pneumoniae, and Mycoplasma pneumoniae This
multicenter evaluation provides data obtained from 1,994
71 ay not be generalizable to the international
multicenter experience.
72 This registry represents the longest
multicenter follow-up of primary left ventricular assist
73 in patients with beyond-MC HCC from the U.S.
Multicenter HCC Transplant Consortium (20 centers, 2002-
74 ithout (n = 2637) cPR from the United States
Multicenter HCC Transplant Consortium (UMHTC), and multi
75 etest, single posttest quasi-experiment in a
multicenter health system in Michigan from 12 March to 2
76 We conducted a
multicenter,
historical cohort study to identify feature
77 This is an international,
multicenter,
hospital-based, retrospective cohort study.
78 n of the presence of previously unconsidered
multicenter "
hyperbonding" (lone-pair-antibonding-orbita
79 PROMISE (Prospective
Multicenter Imaging Study for Evaluation of Chest Pain)
80 ive chart review compared patients seen in a
multicenter institutional practice with DME exhibiting a
81 In this
multicenter intent-to-treat study, DAA therapy was not f
82 ted with clinical characteristics in a large
multicenter international dataset.
83 110 consecutive patients were enrolled in a
multicenter international registry.
84 ty of published data about the issue, future
multicenter international studies will be helpful.
85 In this open-label, single-arm,
multicenter,
international pilot study, adults with rece
86 A recent
multicenter,
international randomized controlled trial s
87 Patients in this
multicenter,
international randomized controlled trial w
88 This is an observational,
multicenter,
international study.
89 In this prospective,
multicenter,
international, observational study, we enro
90 respiratory failure.Methods: We conducted a
multicenter,
international, retrospective cohort study u
91 This
multicenter,
investigator-blind, phase 3, parallel-group
92 The primary objective in this phase 1
multicenter,
investigator-initiated study was to determi
93 allocation system (KAS) and growth of large,
multicenter kidney-paired donation (KPD) clearinghouses
94 al analysis evaluated patients with HCC in a
multicenter,
longitudinal study of AHP.
95 Here we report a
multicenter "
modern-era" validation study that included
96 or Enteric Fever in Asia Project (SEAP) is a
multicenter,
multicountry study conducted in Pakistan, N
97 ADVICE4U was a six-month,
multicenter,
multinational, parallel, randomized control
98 This is a
multicenter,
multisurgeon study of emmetropic presbyopes
99 This was a prospective,
multicenter (
n = 14), observational study of 265 hospita
100 retrospectively identified LGE MRI data in a
multicenter (
n = 7) and multivendor (n = 3) HCM study ob
101 e AIDS Malignancy Consortium 084 study was a
multicenter national trial to evaluate the prevalence of
102 201 blood cultures from 28,011 patients at a
multicenter network of hospitals within New York City to
103 METHODS/DESIGN:
Multicenter non-inferiority randomised controlled clinic
104 For this open-label, pragmatic,
multicenter,
non-inferiority, randomized controlled tria
105 In this open-label,
multicenter,
noninferiority trial, we recruited patients
106 DESIGN, SETTING, AND PARTICIPANTS:
Multicenter,
noninferiority, point-of-care randomized cl
107 Onyx ONE Clear was a prospective,
multicenter,
nonrandomized study evaluating the safety a
108 model was derived using 509 subjects from a
multicenter North American cohort and validated in an in
109 off-label use of Tpo-RAs during pregnancy, a
multicenter observational and retrospective study was co
110 At eight of 16 participant centers, this
multicenter observational study identified validation pa
111 A
multicenter observational study of patients diagnosed wi
112 , a meta-analysis, and a large international
multicenter observational study suggest that extracorpor
113 Multicenter observational study using data from four lar
114 A cross-sectional
multicenter observational study was carried out between
115 In a
multicenter observational study, 290 patients with CM we
116 m 89 patients with AH who were enrolled in a
multicenter observational study, 36 with alcohol use dis
117 der on Outcomes of Young AMI Patients) was a
multicenter,
observational cohort study of 3501 young ad
118 A retrospective,
multicenter,
observational cohort study was performed.
119 (ETIS) registry is an ongoing, prospective,
multicenter,
observational study that perform EVT in Fra
120 We conducted a
multicenter,
open label, randomized controlled trial in
121 A
multicenter,
open-label, 24-week trial (VBP15-003) with
122 SIMPL'HIV was a
multicenter,
open-label, non-inferiority randomized tria
123 We performed a
multicenter,
open-label, randomized controlled trial at
124 In this
multicenter,
open-label, randomized phase II investigato
125 This phase 4,
multicenter,
open-label, randomized, control trial enrol
126 A
multicenter,
open-label, repeated-dose, phase I study wa
127 This
multicenter,
open-label, single-arm, 2-stage clinical tr
128 ion dose alternative to DM.PurposeTo compare
multicenter outcomes from breast cancer screening with S
129 DESIGN, SETTING, AND PARTICIPANTS:
Multicenter,
parallel-group, open-label randomized clini
130 enrolled in the prospective, international,
multicenter PARIS registry (Patterns of Non-Adherence to
131 and warrant further investigation in a large
multicenter phase 3 trial.
132 The SAKK trial 75/08 was a
multicenter phase III trial (NCT01107639) comparing indu
133 le-blind, active-controlled, parallel-group,
multicenter,
phase 3 noninferiority study that compared
134 TANGO is an open-label,
multicenter,
phase 3 study that randomized adults (1:1,
135 INFORM is a randomized,
multicenter,
phase II trial comparing pathologic complet
136 I-SPY 2 is a
multicenter,
phase II, open-label, adaptively randomized
137 to an HIV+ donor, we performed a prospective
multicenter pilot study comparing HIV D+/R+ vs HIV-negat
138 In this
multicenter pilot study directly comparing HIV D+/R+ wit
139 This
multicenter pilot trial assessed the safety, tolerabilit
140 In this phase 2,
multicenter,
placebo-controlled, double-blind, parallel-
141 SETTING, AND PARTICIPANTS: A retrospective,
multicenter,
population-based cohort study of adults wit
142 We conducted a
multicenter,
population-based, prospective study includi
143 DESIGN, SETTING, AND PARTICIPANTS: A
multicenter,
pragmatic, randomized clinical trial was co
144 The Quilty effect will be the subject of a
multicenter project to explore whether it functions as a
145 In 228 patients with HFpEF from the
multicenter PROMIS-HFpEF study (Prevalence of Microvascu
146 STOP-Coinfection was a
multicenter prospective and retrospective, open-label st
147 tilized the baseline data from IMI DIRECT, a
multicenter prospective cohort study of 3,029 European-a
148 In a
multicenter prospective cohort, baseline mean airway pre
149 (mean age 42 +/- 17 years, 97 males) in this
multicenter prospective registry.
150 This
multicenter prospective study evaluated the performance
151 Multicenter prospective study of a birth cohort consisti
152 In this
multicenter prospective study, this strategy of LVAD sup
153 In a
multicenter,
prospective clinical trial (n = 278), we de
154 A secondary analysis of a
multicenter,
prospective cohort study including patients
155 A
multicenter,
prospective cohort study was performed in 2
156 This
multicenter,
prospective trial enrolled 452 women presen
157 Multicenter,
prospective trials with sufficient statisti
158 In this
multicenter,
prospective, observational cohort study, we
159 Multicenter,
prospective, observational study of adult h
160 We conducted a
multicenter,
prospective, open-label, randomized, contro
161 ation Therapy for Heart Failure) trial was a
multicenter,
prospective, randomized, controlled trial;
162 Assist System was an investigator-initiated
multicenter,
prospective, single-arm database establishe
163 Multicenter randomised trial in 15 hospitals in the Neth
164 The TVT Study is a
multicenter randomized clinical trial comparing the safe
165 ic Acid and Zinc Supplementation Trial was a
multicenter randomized clinical trial.
166 and prednisone (R-CHOP; or variant) across 7
multicenter randomized clinical trials to determine whic
167 In a post hoc analysis of a
multicenter randomized controlled trial of CCTA in patie
168 It was based on a 2-arm
multicenter randomized controlled trial with blinded out
169 iovascular events and self-rated health in a
multicenter randomized controlled trial.
170 DESIGN, SETTING, AND PARTICIPANTS:
Multicenter randomized double-blind sequential trial con
171 This was a
multicenter randomized health services study performed w
172 We conducted an international
multicenter randomized phase II study in 60 centers betw
173 This is a French
multicenter randomized phase II trial in patients with r
174 The DESSOLVE III trial (
Multicenter Randomized Study of the MiStent Sirolimus El
175 This
multicenter randomized trial aimed at objectifying the e
176 DESIGN, SETTING, AND PARTICIPANTS:
Multicenter randomized trial conducted from February 8,
177 is strategy warrants further evaluation in a
multicenter randomized trial.
178 The external validity of
multicenter randomized trials in cancer treatment has be
179 SETTING, AND PATIENTS: Secondary analysis of
multicenter randomized trials of critically ill adults i
180 We report results from a
multicenter,
randomized clinical trial (N=535) of the ef
181 al Infarction) is an investigator-initiated,
multicenter,
randomized clinical trial adding 1.8 g n-3
182 We conducted a UK-based
multicenter,
randomized controlled trial to compare outc
183 with ciprofloxacin, at Day 14.Methods: In a
multicenter,
randomized double-blind placebo-controlled
184 We conducted a
multicenter,
randomized trial in the United Kingdom that
185 In this
multicenter,
randomized trial, we assigned patients with
186 This
multicenter,
randomized, assessor-blinded trial tested t
187 DESIGN, SETTING, AND PARTICIPANTS:
Multicenter,
randomized, double-blind, parallel-group tr
188 We designed a
multicenter,
randomized, double-blind, placebo-controlle
189 This was a
multicenter,
randomized, double-blind, placebo-controlle
190 This is the first
multicenter,
randomized, masked, and controlled study de
191 nts in Atrial Fibrillation (PRAGUE-17) was a
multicenter,
randomized, noninferiority trial comparing
192 We performed a
multicenter,
randomized, noninferiority trial to compare
193 The NEVERWOUND study is a 3-month,
multicenter,
randomized, open-label study designed to ev
194 DESIGN, SETTING, AND PARTICIPANTS:
Multicenter,
randomized, open-label, clinical trial cond
195 In a 16-week,
multicenter,
randomized, open-label, parallel-group tria
196 We conducted a
multicenter,
randomized, open-label, three-group, contro
197 DESIGN, SETTING, AND PARTICIPANTS:
Multicenter,
randomized, parallel-group clinical trial c
198 A
multicenter,
randomized, single-blind, two-arm, parallel
199 or patients with IPF.Methods: We performed a
multicenter RCT in newly treated patients with IPF.
200 In this blinded,
multicenter RCT, patients scheduled for elective LVHR (h
201 Data were entered retrospectively into a
multicenter registry for patients who underwent attempte
202 roject on Outcomes - Quality Improvement), a
multicenter registry launched in 2015, instituted qualit
203 Data from a
multicenter registry of 725 cardiac resynchronization th
204 In this prospective,
multicenter registry, NIRS was performed in patients und
205 levation myocardial infarction included in a
multicenter registry.
206 Multicenter retrospective analysis of children who under
207 This was a
multicenter retrospective cohort study using clinical da
208 This report describes the first
multicenter retrospective comparison of the performance
209 This is a
multicenter retrospective study comparing cDCD LT with N
210 This
multicenter retrospective study describes the rate and s
211 Methods: A
multicenter retrospective study enrolled patients who ha
212 Materials and Methods This
multicenter retrospective study evaluated 540 adults wit
213 This is a
multicenter retrospective study including 104 patients w
214 This
multicenter retrospective study reports outcomes for adu
215 The Durable MCS after ECLS registry is a
multicenter retrospective study that gathered data on co
216 We conducted a French
multicenter retrospective study that included 45 patient
217 We conducted a
multicenter retrospective study to describe the incidenc
218 Methods: In a
multicenter retrospective study, bone scans from patient
219 We conducted a
multicenter,
retrospective cohort study of injury deaths
220 A
multicenter,
retrospective, cross-sectional study of ped
221 In a longitudinal,
multicenter sample of 3,565 magnetic resonance imaging (
222 Work is ongoing to confirm our findings in a
multicenter setting and on longer-term clinical outcomes
223 in patients with dilated cardiomyopathy in a
multicenter setting as part of an emerging global consor
224 lly HLA-matched donors has shown efficacy in
multicenter settings.
225 ere retrieved from the randomized controlled
multicenter SiLVER trial.
226 PRECEPT was a prospective,
multicenter,
single-arm Food and Drug Administration-reg
227 The aim of this prospective,
multicenter,
single-arm study was to evaluate the feasib
228 s a large-scale, registry-based, randomized,
multicenter,
single-blind, 2-arm, noninferiority trial.
229 ATE-AF) trial was an investigator-initiated,
multicenter,
single-blind, randomized clinical trial con
230 Coronary Arteries; n=1398) is a prospective,
multicenter,
single-blinded, all-comers, randomized cont
231 In the
multicenter SPINS (Stress CMR Perfusion Imaging in the U
232 Patient-based TTV may be preferred for
multicenter studies because its repeatability was both h
233 Future prospective
multicenter studies should validate their role as a diag
234 The Global Enteric
Multicenter Study (GEMS) was a 3-year case-control study
235 We conducted a prospective,
multicenter study (NEXT-in-CML) to assess the frequency
236 re enrolled in a prospective, observational,
multicenter study across the United States.
237 This retrospective European
multicenter study aimed to assess the sustained virologi
238 This
multicenter study assessed the performance of the cobas
239 A nationwide
multicenter study based on the Italian Primary Immunodef
240 This international
multicenter study by the Upper GI International Robotic
241 This
multicenter study compared the investigational-use-only
242 We performed a
multicenter study comparing 13 commonly used scRNA-seq a
243 Conclusion This
multicenter study demonstrated early and progressive inv
244 (NCT03595176) was a prospective, single-arm
multicenter study designed for regulatory approval of co
245 Methods: This prospective
multicenter study enrolled 260 men between 2015 and 2017
246 A prospective, split-mouth,
multicenter study evaluated scaling and root planing (SR
247 This
multicenter study evaluated the outcome of DAIR in relat
248 This
multicenter study identifies insights into the risk fact
249 We conducted a
multicenter study in the United States of 112 adult LT r
250 This
multicenter study included 29 consecutive patients with
251 This
multicenter study included 7 tertiary care neuro-ophthal
252 This international
multicenter study included 8 comprehensive stroke center
253 This
multicenter study included consecutive adult patients wi
254 Methods: This retrospective
multicenter study included patients who had cCR after nC
255 This
multicenter study included sites in the United Kingdom a
256 evaluate the performance of this method in a
multicenter study including 16 teaching hospitals in the
257 This was a
multicenter study including 4949 patients who underwent
258 Here we report a large-scale
multicenter study involving training and validation coho
259 In this observational cross-sectional
multicenter study of 340 patients, we evaluated the impa
260 We performed a retrospective
multicenter study of 712 patients with CGD who underwent
261 This international
multicenter study of CASQ2-CPVT redefines its heritabili
262 We performed a retrospective
multicenter study on bronchoalveolar lavage fluid (BALF)
263 y assess these links, we performed the first
multicenter study on emotion recognition and interocepti
264 This
multicenter study population included 1 eye of both 930
265 These data support a larger, longer,
multicenter study to determine the safety and efficacy o
266 Methods A prospective international
multicenter study was conducted on 186 consecutive FD pa
267 A
multicenter study was performed to establish the perform
268 Retrospective
multicenter study within the Paediatric Tuberculosis Net
269 Using data from the Global Enteric
Multicenter Study, we assessed whether acute malnutritio
270 In an institutional review board-approved
multicenter study, we carried out a retrospective analys
271 In this
multicenter study, we compared the performance of the Si
272 In this phase 2
multicenter study, we evaluated the incorporation of aut
273 In this retrospective,
multicenter study, we have investigated the role of surv
274 hods: Sixteen patients were included in this
multicenter study.
275 ival, but has not been evaluated in a large,
multicenter study.
276 logies were evaluated in this retrospective,
multicenter study.
277 dy are encouraging and warrant a prospective
multicenter study.
278 The
multicenter Transfusion Requirements in Transcatheter Ao
279 nced disease were enrolled in this phase II,
multicenter trial and randomly assigned to receive afati
280 Our
multicenter trial demonstrated safety and efficacy of tr
281 Imaging Network Cancer Research Group A6702
multicenter trial helped confirm the potential of diffus
282 We performed a
multicenter trial in which patients 18 to 80 years of ag
283 andomized, double-blind, placebo-controlled,
multicenter trial of 789 patients with chronic HFpEF and
284 In the
Multicenter Trial of Cryotherapy for Retinopathy of Prem
285 This
multicenter trial provides data regarding the associatio
286 We conducted a phase II,
multicenter trial to assess the efficacy and safety of b
287 olled in a double-blind, placebo-controlled,
multicenter trial using GRAZAX(R) during 2 years.
288 In this phase III
multicenter trial, 307 patients with OC were randomly as
289 andomized, double-blind, placebo-controlled,
multicenter trial, patients with >=1 SVGs were randomly
290 were included in our double-blind phase III
multicenter trial.
291 ese results need validation in a prospective
multicenter trial.
292 We designed an open-label, randomized,
multicenter,
two-arm phase II trial to investigate cispl
293 We conducted a
multicenter,
two-group, randomized, placebo-controlled t
294 s infection in this geographically dispersed
multicenter UK cohort indicates that this condition shou
295 trum of BK infection (n = 25), followed by a
multicenter validation cohort of allograft BKVN (n = 60)
296 This
multicenter validation study compared the prognosticatio
297 identify a set of imaging markers robust to
multicenter variation and to derive upper estimates on s
298 er odds of lead authorship in RCTs that were
multicenter,
were coordinated in North America or Europe
299 Methods: Within a prospective
multicenter whole-genome sequencing trial (NCT01855477),
300 This study included patients from the
Multicenter Zurich ARVC Registry who hosted a genetic va